Home » Stocks » KALV

KalVista Pharmaceuticals, Inc. (KALV)

Stock Price: $16.24 USD -0.74 (-4.36%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
Market Cap 312.37M
Revenue (ttm) 5.40M
Net Income (ttm) -37.12M
Shares Out 17.91M
EPS (ttm) -2.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $16.24
Previous Close $16.98
Change ($) -0.74
Change (%) -4.36%
Day's Open 17.20
Day's Range 16.07 - 18.18
Day's Volume 143,957
52-Week Range 5.80 - 19.47

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 week ago

Investors need to pay close attention to KalVista Pharmaceuticals (KALV) stock based on the movements in the options market lately.

Zacks Investment Research - 1 month ago

KalVista Pharmaceuticals (KALV) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Business Wire - 1 month ago

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, ...

Business Wire - 2 months ago

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, ...

Business Wire - 3 months ago

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, a...

Business Wire - 4 months ago

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc.

Business Wire - 4 months ago

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc.

Business Wire - 5 months ago

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc.

Business Wire - 6 months ago

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, ...

GuruFocus - 9 months ago

Sell-side analysts on Wall Street recommend to buy shares of Stemline Therapeutics Inc (NASDAQ:STML) and KalVista Pharmaceuticals Inc (NASDAQ:KALV), even though their share prices have lost mo...

Other stocks mentioned: STML
GuruFocus - 9 months ago

Sell-side analysts on Wall Street recommend to buy shares of Stemline Therapeutics Inc (NASDAQ:STML) and KalVista Pharmaceuticals Inc (NASDAQ:KALV), even though their share prices have lost mo...

Other stocks mentioned: STML
Zacks Investment Research - 11 months ago

Here are five defensive stocks that can shield your portfolio as Covid-19 continues to spread, instilling volatility in the stock market.

Other stocks mentioned: DVA, ENSG, MEIP, RMD
Zacks Investment Research - 11 months ago

Here are five defensive stocks that can shield your portfolio from China's coronavirus that intimidates to weigh on the stock market.

Other stocks mentioned: CDNA, CVGW, DAR, SMPL
Zacks Investment Research - 11 months ago

As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals.

Zacks Investment Research - 11 months ago

Prospects Appear Bright for Small Drug Industry in 2020

Other stocks mentioned: AMRX, COLL, MTNB
Benzinga - 1 year ago

Shares of thinly-traded micro-cap biotech Kalvista Pharmaceuticals Inc (NASDAQ: KALV) are seen moving to the downside Monday.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals, Inc. (KALV).

Zacks Investment Research - 1 year ago

KalVista Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research - 1 year ago

KalVista Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

InvestorPlace - 1 year ago

These are five stocks to consider buying because of significant insider buying activity. Insiders only buy for one reason: to make money.

Other stocks mentioned: FDX, HRTX, IMMU, VBIV
Zacks Investment Research - 1 year ago

KalVista Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Seeking Alpha - 1 year ago

KALV is an early stage company without much efficacy data, but early data for its drug candidates are promising.

Seeking Alpha - 1 year ago

Clinical-stage biopharma KalVista Pharmaceuticals has lost approximately 40% of its value since early April as it entered a news vacuum.

Seeking Alpha - 1 year ago

KalVista's valuation continues to drift but it has two things going for it: cash runway & catalysts.

Zacks Investment Research - 1 year ago

KalVista Pharmaceuticals, Inc. (KALV) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Seeking Alpha - 1 year ago

Shares of KalVista have fallen nearly 30% this month due to sector weakness and insider sales (presumably).

Zacks Investment Research - 1 year ago

KalVista Pharmaceuticals (KALV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 1 year ago

Does KalVista Pharmaceuticals (KALV) have what it takes to be a top stock pick for momentum investors? Let's find out.

About KALV

KalVista Pharmaceuticals, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treati... [Read more...]

Industry
Biotechnology
CEO
Thomas Crockett
Employees
56
Stock Exchange
NASDAQ
Ticker Symbol
KALV
Full Company Profile

Financial Performance

In 2020, KALV's revenue was $12.69 million, a decrease of -21.31% compared to the previous year's $16.13 million. Losses were -$29.12 million, 39.9% more than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for KALV stock is "Strong Buy." The 12-month stock price forecast is 29.86, which is an increase of 83.87% from the latest price.

Price Target
$29.86
(83.87% upside)
Analyst Consensus: Strong Buy